Table 3.

Baseline demographic and clinical characteristics by patient diagnosis

SMAMLMDS/CMMLHESCELPMF
n33 (9 ASM, 18 ISM, 6 SM-AHNMD)*96 (3 MDS, 3 CMML)5311
Median age, y (range)57 (29-74)70 (57-91)68 (61-75)48 (23-71)68 (62-75)63 (43-77)
Sex (M:F)14:197:24:23:22:110:1
CytogeneticsDiploid: 30Diploid: 5Diploid: 5Diploid: 5Diploid: 0Diploid: 9
Complex (≥3 abn): 1+(8): 1+(8): 0+(8): 1Complex (≥3 abn): 2
Unknown: 2−(7): 1−(7): 0Complex (≥3 abn): 1
Other: 2Other: 1§Other: 1
Performance status
    0012201
    13174228
    2210112
Number of prior therapies
    01613012
    11221404
    2441013
    3020111
    ≥4101001
Prior therapies (no. patients indicated if >1)Imatinib (8); denileukin diftitox (4), IFN (3); darbepoetin (4); cladribine (4); 17-AAG; PKC412Idarubicin + cytarabine (5); fludarabine + cytarabine; high-dose cytarabine; cytarabine + tipifarnib; allo BMT; VNP40101M; perifosine; sapacitabine; thalidomide; azacitidine; hydroxyureaPeg-IFN, lenalidomide, PTK787 + imatinib; thalidomide; decitabine (2); hydroxyurea; clofarabine + cytarabineImatinib (2); peg-IFN; nilotinibEpoetin; hydroxyurea; idarubicin + cytarabine; decitabine + valproic acid; imatinibPTK787 (3); lenalidomide (2); IFN, thalidomide; etanercept, imatinib, RAD001, hydroxyurea (5); azacitidine (3); peg-IFN, anagrelide
  • Abbreviations: Abn, abnormalities; allo BMT, allogeneic BM transplantation; MPD, myeloproliferative disease; peg-IFN, pegylated IFN alfa; 17-AAG, 17-(allylamino)-17-demethoxygeldanamycin.

  • * CEL (1), MF (1), MDS/MPD (1), and CMML (3).

  • Insufficient metaphase.

  • 20q- and i(17q).

  • § t(15;19).

  • t(5;12)(q31;p13).